Voya Investment Management LLC Sells 50,947 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Voya Investment Management LLC lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 816,893 shares of the biopharmaceutical company's stock after selling 50,947 shares during the quarter. Voya Investment Management LLC owned approximately 0.07% of Gilead Sciences worth $75,456,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of GILD. Integrated Wealth Concepts LLC increased its holdings in Gilead Sciences by 4.7% in the 4th quarter. Integrated Wealth Concepts LLC now owns 26,687 shares of the biopharmaceutical company's stock valued at $2,465,000 after buying an additional 1,194 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in Gilead Sciences in the fourth quarter worth about $158,334,000. Syon Capital LLC lifted its stake in Gilead Sciences by 25.5% during the fourth quarter. Syon Capital LLC now owns 18,079 shares of the biopharmaceutical company's stock worth $1,670,000 after purchasing an additional 3,678 shares during the period. MGO One Seven LLC raised its stake in Gilead Sciences by 70.8% during the fourth quarter. MGO One Seven LLC now owns 11,195 shares of the biopharmaceutical company's stock worth $1,034,000 after acquiring an additional 4,639 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Gilead Sciences by 5.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,546,721 shares of the biopharmaceutical company's stock valued at $327,612,000 after purchasing an additional 198,528 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $17,597,559.49. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 302,785 shares of company stock valued at $30,540,875 over the last 90 days. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Performance

Shares of GILD stock traded up $0.60 on Wednesday, reaching $104.81. The stock had a trading volume of 2,761,127 shares, compared to its average volume of 7,495,770. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $130.51 billion, a price-to-earnings ratio of 283.27, a P/E/G ratio of 0.71 and a beta of 0.32. The firm's 50-day moving average is $109.07 and its two-hundred day moving average is $98.52.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same period last year, the firm posted ($1.32) EPS. The firm's revenue for the quarter was down .3% compared to the same quarter last year. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.01%. Gilead Sciences's payout ratio is currently 66.53%.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research reports. Morgan Stanley raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a report on Thursday, February 13th. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada raised their price objective on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus price target of $109.43.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.